Clinical trials: Cancer, Metastatic
Malignant Melanoma
A Study of RO5185426 in Previously Treated Melanoma Patients With Brain Metastases
This open-label study will assess the safety and efficacy of RO5185426 in previously treated metastatic melanoma patients with brain metastases.
- Trial name
- NCT01253564
- Testing
- RO5185426
- Where
- 2 sites in Switzerland
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
Castration Resistant Metastatic Prostate Cancer
Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance
Asymptomatic men with progressive metastatic Castration-resistant prostate cancer (CRPC) post- treatment with abiraterone acetate (pre-chemotherapy for metastatic disease) will be treated on a randomized, multi-Institutional open…
- Trial name
- Transformer (NCT02286921)
- Testing
- Testosterone cypionate, Enzalutamide, Testosterone Enanthate
- Where
- 17 sites in United States
- Volunteers
- 222 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Castration-Resistant Prostate Cancer
Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer
The purpose of the phase 2 study is to determine whether Onvansertib is safe and tolerable in adult participants with Metastatic Castration-Resistant Prostate Cancer who have disease progression while receiving abiraterone…
- Trial name
- NCT03414034
- Testing
- Onvansertib, Abiraterone, Prednisone
- Where
- 3 sites in United States
- Volunteers
- 72 people
- Sponsor
- Cardiff Oncology
Breast Neoplasms
Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer
The objective of this study was to assess efficacy and safety of radium-223 dichloride in subjects with human epidermal growth factor receptor 2 negative (HER2 negative) hormone receptor positive breast cancer with bone…
- Trial name
- NCT02258464
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223), Background hormonal therapy
- Where
- 71 sites in United States, Austria and 18 more
- Volunteers
- 99 people
- Sponsor
- Bayer
BRAF V600E Mutation Positive, Metastatic Colorectal Cancer
A Retrospective Non Interventional Study on First Line Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)
The presence of a BRAFV600E mutation is considered a marker of poor prognosis in patients with mCRC, and findings from clinical trials have largely remained inconclusive regarding the efficacy of first line treatments for…
- Trial name
- CAPSTAN CRC (NCT04317599)
- Testing
- Non interventional
- Where
- 34 sites in Austria, Belgium and 5 more
- Volunteers
- 274 people
- Sponsor
- Pierre Fabre Medicament
Breast Cancer
A Study of Pemetrexed and Cyclophosphamide Given Every 21 Days in Advanced Breast Cancer Patients
This is the phase 2 portion of a phase 1/2 trial, testing the use of pemetrexed and cyclophosphamide in combination for the treatment of advanced breast cancer.
- Trial name
- NCT00190671
- Testing
- pemetrexed, cyclophosphamide
- Where
- 13 sites in Austria, Czechia and 4 more
- Volunteers
- 103 people
- Sponsor
- Eli Lilly and Company
Cholangiocarcinoma
Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma
Patients with advanced or metastatic cholangiocarcinoma (CCA) who are not eligible for curative surgery, transplantation, or ablative therapies will receive nab-paclitaxel and gemcitabine chemotherapy.
- Trial name
- PrE0204 (NCT02181634)
- Testing
- Nab-Paclitaxel and Gemcitabine
- Where
- 25 sites in United States, Austria
- Volunteers
- 74 people
- Sponsor
- PrECOG, LLC.
Hepatocellular Cancer, AFP Expressing Tumors
AFPᶜ³³²T in Advanced HCC
This first time in human study is intended for men and women between 18 and 75 years of age who have advanced liver cancer which has grown or returned after being treated or another AFP expressing tumor.
- Trial name
- NCT03132792
- Testing
- Autologous genetically modified AFPᶜ³³²T cells
- Where
- 21 sites in United States, France and 2 more
- Volunteers
- 39 people
- Sponsor
- Adaptimmune
Metastatic Clear Cell Renal Cell Carcinoma, Recurrent Clear Cell Renal Cell Carcinoma
Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery
This phase II trial studies how well pembrolizumab with or without standard of care axitinib works in treating patients with clear cell kidney cancer that has spread to nearby tissues or lymph nodes (locally advanced) or other…
- Conditions
- Metastatic Clear Cell Renal Cell Carcinoma, Recurrent Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Trial name
- NCT04370509
- Testing
- Axitinib (VEGF-TKI), Cytoreductive Nephrectomy (CN), Metastasectomy (MET)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, San Francisco
Breast Cancer
A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
The main purpose of this study is to evaluate how effective nonsteroidal aromatase inhibitors (NSAI) plus abemaciclib are in postmenopausal women with breast cancer.
- Trial name
- MONARCH 3 (NCT02246621)
- Testing
- Abemaciclib, Anastrozole, Letrozole
- Where
- 155 sites in United States, Australia and 20 more
- Volunteers
- 493 people
- Sponsor
- Eli Lilly and Company
Neoplasms
Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer
This is a combination Phase I and Phase II study, with an aim to evaluate the combination of GSK525762 and fulvestrant in women with HR+/HER2- advanced or metastatic breast cancer, who have disease that has progressed after prior…
- Trial name
- NCT02964507
- Testing
- GSK525762, Fulvestrant
- Where
- 38 sites in United States, Australia and 5 more
- Volunteers
- 124 people
- Sponsor
- GlaxoSmithKline
Malignant Salivary Gland Neoplasm, Recurrent Salivary Gland Carcinoma
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
This phase II trial is studying how well dasatinib works in treating patients with malignant salivary gland tumors that have come back after treatment or have spread to other parts of the body.
- Conditions
- Malignant Salivary Gland Neoplasm, Recurrent Salivary Gland Carcinoma, Salivary Gland Adenoid Cystic Carcinoma, Stage IV Major Salivary Gland Cancer AJCC v7
- Trial name
- NCT00859937
- Testing
- Dasatinib, Laboratory Biomarker Analysis
- Where
- 34 sites in United States, Canada
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Cancer, Prostate Cancer
ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A Phase 1/2 multicenter, dose determining, open-label study of ADXS31-142 monotherapy and a combination of ADXS31-142 and pembrolizumab (MK-3475) in participants with metastatic castration-resistant prostate cancer.
- Trial name
- NCT02325557
- Testing
- ADXS31-142, Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 50 people
- Sponsor
- Advaxis, Inc.
Cervical Carcinoma
Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma
Prospective, multicenter, multiple cohort, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (LN-145), with or without pembrolizumab, followed by…
- Trial name
- NCT03108495
- Testing
- LN-145, LN-145 + pembrolizumab
- Where
- 43 sites in United States, France and 6 more
- Volunteers
- 210 people
- Sponsor
- Iovance Biotherapeutics, Inc.
Adenoid Cystic Carcinoma
Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma
The purpose of this study is to improve survival of patients with recurrent or metastatic Adenoid Cystic Carcinoma (ACC). This study will test the efficacy of the investigational drug, TKI258, in treating ACC.
- Trial name
- ACC (NCT01524692)
- Testing
- Dovitinib (TKI258)
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Virginia
Breast Cancer, Cancer of the Breast
Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy
This trial seeks to confirm the response rate for estrace treatment in a patients with hormone receptor positive metastatic breast cancer heavily pre-treated with modern endocrine therapies.
- Conditions
- Breast Cancer, Cancer of the Breast, Neoplasms, Breast
- Trial name
- NCT00661531
- Testing
- Estrace, Anastrozole
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Georgetown University
Metastatic Renal Cell Carcinoma
A Study for Participants With Metastatic Renal Cell Carcinoma
This study will compare the effects of Enzastaurin plus Sunitinib versus Sunitinib alone in metastatic Renal Cell Cancer.
- Trial name
- NCT00709995
- Testing
- Enzastaurin, Sunitinib
- Where
- 4 sites in Austria, France and 2 more
- Volunteers
- 17 people
- Sponsor
- Eli Lilly and Company
Malignant Peripheral Nerve Sheath Tumors (MPNST), Sarcoma
SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)
Phase 1: To assess the safety, tolerability, and maximum tolerated dose (MTD)/ recommended dose of ganetespib when administered in combination with sirolimus in patients with refractory or relapsed sarcomas including unresectable…
- Trial name
- NCT02008877
- Testing
- ganetespib, Sirolimus
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Metastatic Breast Cancer
Survival Endpoints in Women Treated for Metastatic Breast Cancer: Contribution of Real-life Databases
Overall survival (OS) is considered the most reliable cancer endpoint and used by the Health Rregulatory authorities (HRA). OS presents multiple advantages in cancer randomized controlled trials (RCT): it is universally accepted…
- Trial name
- NCT03676257
- Testing
- Chemotherapy (exclusive), Endocrine therapy (exclusive), Combination of endocrine therapy and chemotherapy
- Where
- France
- Volunteers
- 20,033 people
- Sponsor
- Institut Bergonié
Brain Metastases
Study to Establish Image Interpretation Criteria for 18F Fluciclovine PET in Detecting Recurrent Brain Metastases (PURSUE)
An Open-label, Single-arm, Single-dose, Prospective, Multicenter Phase 2b Study to Establish Image Interpretation Criteria for 18F-Fluciclovine Positron Emission Tomography (PET) in Detecting Recurrent Brain Metastases After…
- Trial name
- PURSUE (NCT04410367)
- Testing
- 18F fluciclovine
- Where
- 9 sites in United States
- Volunteers
- 23 people
- Sponsor
- Blue Earth Diagnostics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.